Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that serum GPER-1 levels were significantly higher in patients with androgenetic alopecia compared to healthy controls, suggesting a potential role in the condition's pathogenesis, independent of gender.

This study developed BroadAMP-GPT, a computational-experimental framework, to discover new antimicrobial peptides, identifying candidates effective against multidrug-resistant pathogens. Notably, AMP_S13 showed strong stability, low toxicity, and efficacy in infection models, highlighting the platform's potential in combating antimicrobial resistance.

In this study, the researchers developed an optimal emulgel formulation for treating androgenic alopecia, determining that a base with 0.3% Carbomer Ultraz 10, 0.1% potassium sorbate, and 0.2% triethanolamine offered the best properties for drug release, application compliance, safety, and stability.

This article reviews the development and challenges of skin penetration enhancers, highlighting their limitations in compatibility and safety, and reports no new clinical findings.

This study found that nonablative Er:YAG laser therapy effectively improved hair appearance for patients with androgenetic alopecia, with most participants reporting increased satisfaction and no adverse reactions, following six biweekly sessions.

This study found that water fractions of Angiopteris evecta stimulated hair growth in male rabbits, suggesting potential alopecia treatment benefits pending further research in humans.

This study observed that both prenatal androgen exposure and postnatal early-life environment influence the development of PCOS-like phenotypes and changes in the gut microbiota in prenatally androgenized offspring.

This review discusses the roles of the Agouti and Agouti-related proteins in pigmentation and energy regulation and reports no new experimental findings.

In this case report, a 37-year-old patient with APECED showed significant clinical improvement, including hair regrowth and resolution of skin issues, after 11 months of treatment with ruxolitinib, highlighting the potential of JAK inhibitors in managing this complex autoimmune disease.

This article reviews androgenetic alopecia and its effects but reports no new clinical results, highlighting that current treatments offer only temporary therapeutic benefits.

This study found that serum GPER-1 levels may serve as a biomarker for differentiating androgenetic alopecia from telogen effluvium and healthy controls, although its ability to distinguish between AGA and TE is limited.

This article discusses the challenges of treating androgenetic alopecia due to limited approved medications, potential side effects, and unmet expectations and reports no new clinical results.

This study found that epidermal growth factor receptor inhibitors can induce erosive pustular dermatosis of the scalp, typically appearing sooner and affecting the scalp more extensively compared to other triggers.

Polyethylene alanine caused hair loss in young lab animals but not in adults, with hair regrowth occurring within 20 days.

This study found that palmitoylethanolamide may stimulate allopregnanolone synthesis and reduce oxidative stress in astrocytes through PPAR-α activation, suggesting a neuroprotective role.

This study found that the dietary supplement RJ-SP4AGA significantly improved hair growth and reduced hair loss in post-menopausal women with androgenetic alopecia over 16 weeks.

This study suggests that the AGA risk haplotype in Europeans was driven to high frequency by positive selection, likely associated with a variant in the EDA2R gene.

This article reviews the causes and current treatment options for androgenetic alopecia, reporting no new clinical findings and highlighting the need for more therapeutic choices.

The device improved hair growth and thickness in men without side effects.

In this study involving 15 women with alopecia, subcutaneous scalp injections of platelet-rich plasma every four weeks for three sessions led to increased hair and hair follicle density at 24 weeks, with common side effects being local swelling and pain.

This study found that in a rat model, 14,15-EET may alleviate central poststroke pain by enhancing thalamic inhibition through neurosteroid signaling, potentially outperforming gabapentin in early-stage treatment.

This dataset provides supplemental material for a study on long-term particulate matter exposure and androgenetic alopecia risk, including additional exposure data and sensitivity analyses, but reports no new clinical results.

This study describes a planned multicenter randomized controlled trial to assess the safety, tolerability, and pharmacokinetics of subdermal gestrinone pellets in patients with deep infiltrative endometriosis-related pelvic pain, but it does not report any findings yet.

This review highlights the potential of amphiregulin as a therapeutic target, noting its role in both fibrotic and malignant diseases, and discusses promising early findings but reports no new clinical results.

The study found that patients with androgenetic alopecia had higher serum GPER-1 levels, which were associated with disease severity and duration, indicating a potential estrogen-independent role of GPER-1 in the condition's pathogenesis.

This study describes three cases of acneiform eruptions from EGFR inhibitors that improved with topical recombinant human EGF, suggesting its potential as a treatment option for this side effect.

This review explores the link between androgenetic alopecia, advanced glycation end products, and RAGE, noting their potential role in exacerbating oxidative stress and inflammation related to hair follicle miniaturization.

This study reports that VP-16-213 (etoposide) shows significant therapeutic activity in several cancers including small cell bronchogenic carcinoma and certain leukemias, with hematologic toxicity being the primary side effect.

This review discussed the cutaneous manifestations of APECED, highlighting chronic mucocutaneous candidiasis, alopecia areata, and vitiligo, while emphasizing the importance of early detection and monitoring for accurate diagnosis and patient care in various populations.

This study found that inhibiting the enzyme PDE8A can promote adipocyte differentiation and enhance hair growth in an animal model of androgenetic alopecia, suggesting PDE8A as a potential therapeutic target for restoring dermal adipogenesis and hair cycling.